Unit of Medical Oncology, Department of Oncology, University of Pisa, Pisa, Italy.
Department of Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases, University Cancer Centre Leipzig (UCCL), Leipzig University Medical Centre, Leipzig, Germany.
Best Pract Res Clin Gastroenterol. 2021 Mar-Apr;50-51:101738. doi: 10.1016/j.bpg.2021.101738. Epub 2021 Feb 21.
Gastric cancer is a major cause of cancer-related morbidity and mortality worldwide. Advances in targeted medical treatment were scarce in the past and challenged by the marked spatial and temporal biological heterogeneity of gastric cancer. Recent molecular profiling studies have increased our understanding of genetic and epigenetic drivers, leading to better patient selection for drug development. Beyond that, immune-related biomarkers were identified, paving the way for future effective immunotherapy. We systematically reviewed articles from PubMed of the past 10 years, and abstracts from annual meetings of ESMO, ASCO and AACR to summarise the current knowledge about targeted and immunotherapy and outline pathways to future personalised therapy of gastric cancer.
胃癌是全球癌症相关发病率和死亡率的主要原因。过去，针对这种疾病的靶向药物治疗进展缓慢，而且受到胃癌显著的时空生物学异质性的挑战。最近的分子分析研究增加了我们对遗传和表观遗传驱动因素的了解，从而为药物开发更好地选择患者。除此之外，还确定了与免疫相关的生物标志物，为未来有效的免疫疗法铺平了道路。我们系统地回顾了过去 10 年来自 PubMed 的文章，以及 ESMO、ASCO 和 AACR 年会的摘要，以总结目前关于靶向治疗和免疫治疗的知识，并概述未来胃癌个体化治疗的途径。
